Genmab — Maj 2016
-
I den detaljerede beskrivelse på CT står der: In Part 2, participants with documented epidermal growth factor receptor (EGFR) mutations and measurable disease, whose disease has progressed during treatment with a marketed EGFR inhibitor, will be enrolled and receive JNJ-61186372 at the RP2D determined in Part 1. Så hvis de mutationer er særligt udbredt blandt koreanere, er det nok derfor.
-
The PIONEER study, published in the February issue of the Journal of Thoracic Oncology, tested 1482 patients from 7 Asian regions, and found EGFR mutations at a rate of 51.4% overall. Previous estimates have put the rate at around 30% in Asian patients, and around 20% among white patients.
-
EGFR Mutations Found in Half of Asian NSCLC Patients
The first epidemiologic study of EGFR mutations in Asian patients with adenocarcinoma non-small cell lung cancer (NSCLC) has found a rate of 51.4%.
Medscape (www.medscape.com)
-
Sukkeralf...Har du spørgsmål til Zealand Pharma, så må du godt stille dem senest kl. 11 i morgen.
-
Mon Nordnet kan trække den tur alene?
-
Nyt fra Don. My sweeties and I bought a nice bouquet of yellow roses to celebrate my latest treatment results. These numbers are the lowest that I have seen in my 13 years with myeloma.http://myelomahope.blogspot.de/2016/05/yellow-roses.html
-
Vidunderligt. Får en klump i halsen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind